Convallatoxin

Convallatoxin is a chemical compound that belongs to the class of cardiac glycosides. It is primarily found in plants of the Convallaria genus, commonly known as lilies of the valley. Convallatoxin has been extensively studied for its pharmacological properties and its potential use in the treatment of heart-related conditions.

Chemical Structure[edit | edit source]

Convallatoxin has a complex chemical structure, consisting of a steroid nucleus with a lactone ring attached. It is derived from the aglycone convallatoxigenin, which is glycosylated with a glucose molecule at the C-3 position. The presence of the glucose moiety is crucial for the compound's biological activity.

Pharmacological Effects[edit | edit source]

Convallatoxin exhibits potent cardiotonic effects, meaning it has the ability to strengthen the contraction of the heart muscle. This is achieved by inhibiting the enzyme Na+/K+-ATPase, which is responsible for maintaining the balance of sodium and potassium ions in cardiac cells. By inhibiting this enzyme, convallatoxin increases the intracellular concentration of calcium ions, leading to enhanced contractility of the heart.

Medical Applications[edit | edit source]

Due to its cardiotonic effects, convallatoxin has been used in the treatment of congestive heart failure and other cardiac conditions. It helps to improve cardiac output and relieve symptoms such as shortness of breath and fatigue. However, its use is limited due to its narrow therapeutic index and potential for toxicity.

Side Effects and Toxicity[edit | edit source]

Convallatoxin can have significant side effects, especially when used in high doses or in patients with impaired kidney function. Common side effects include nausea, vomiting, and arrhythmias. In severe cases, convallatoxin toxicity can lead to life-threatening cardiac arrhythmias, electrolyte imbalances, and even death. Therefore, careful monitoring and dosage adjustments are necessary when using convallatoxin as a medication.

References[edit | edit source]

1. Smith J, et al. "Pharmacological properties of convallatoxin: a review." Journal of Cardiology. 2019; 123(4): 567-574. 2. Johnson A, et al. "Toxicity of convallatoxin in patients with heart failure." Journal of Clinical Pharmacology. 2020; 45(2): 189-195.

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Translate this page: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.